Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

Publication | Closed Access

DOI

274

Citations

References

2019

Year

Javier Bolaños‐Meade, Ran Reshef, Raphael Fraser, Mingwei Fei, Sunil Abhyankar, Zaid Al‐Kadhimi, Amin M. Alousi, Joseph H. Antin, Sally Arai, Kate Bickett,

The Lancet Haematology

Versus TacrolimusTransplantationImmunosuppressive TherapyImmunologyHematologyGraft SurvivalProphylaxis RegimensBmt Ctn 1203ImmunotherapyMedicineCell TransplantationGraft Rejection